Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Avenanthramide trial - diabetes management

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Aug 13, 2022 11:56pm

77 Views

Post# 34894731

RE:Avenanthramide trial - diabetes management

Here are the authors of the study... Canada and Quaker Oats:

Affiliations

1Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
2Agriculture & Agri-Food Canada, Winnipeg, Manitoba, Canada.
3Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada.
4Quaker Oats Center of Excellence, PepsiCo R&D Nutrition, Barrington, Illinois, USA.

prophetoffactz wrote: According to CZO's presentation it will examine inflammation and glucoregulation in its avenanthramide clinical trial. Here's some new reseach on glucoregulation:

"Based on our results, we have confirmed for the first time that the glucose uptake is indeed inhibited by the presence of avenanthramides, suggesting the possibility of incorporating avenanthramides in foods to enhance postprandial glucose response, and ultimately improve the management of diabetes. Therefore, future research could consider utilizing this evidence in the development of diabetic-friendly functional foods or nutraceuticals containing avenanthramides."
The inhibition of intestinal glucose absorption by oat-derived avenanthramides - PubMed (nih.gov)